Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SaPPrOC: Saracatinib + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT01196741Phase 3Completed
- Sponsor
- University College London
- Start
- Mar 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of saracatinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University College London. Primary endpoint: 6 Month Progression-free Survival Rate. Started Mar 2011; status: completed.
02
Drugs
saracatinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01196741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01196741.